Table 5.
Summary: Gla-300 compared to Gla-100
| Insulin | Gla-300 | Gla-100 |
|---|---|---|
| Brand name | Toujeo® | Lantus® |
| Manufacturer | Sanofi-Aventis | Sanofi-Aventis |
| US FDA approval (year) | 2015 | 2000 |
| Vial or pen delivery | Pen | Vial and pen |
| Dosage form | • 1.5 mL SoloStar disposable prefilled pen (package of 3 and 5) | • 10 mL vial • 3 mL SoloStar prefilled pen (package of 5) |
| Maximum single dose delivery of pen (units/dose) | 80 | 80 |
| Expiration in-use (opened) pen | 28 days room temperature only (do not refrigerate) | 28 days room temperature only (do not refrigerate) |
| Duration of activity | >24 h (up to 36 h) | 24 h |
| Clinical considerations: Gla-300 vs Gla-100 | ||
| Change in HbA1c | Noninferior | |
| Basal insulin dose | 10%–18% higher dose vs Gla-100 | |
| Body weight | Similar or smaller weight increase vs Gla-100 | |
| Nocturnal hypoglycemia | 21%–23% reduction only in insulin-experienced patients with T2DM | |
| Anytime hypoglycemia | No difference | |
Abbreviations: Gla-100, insulin glargine 100 U/mL; Gla-300, insulin glargine 300 U/mL; T2DM, type 2 diabetes mellitus; h, hours.